DescriptionCurator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitracin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2364036 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | BACITRACIN Approved UseUses first aid to help prevent infection in: •minor cuts •scrapes •burns Launch Date1948 |
|||
| Curative | CORTISPORIN Approved UseFor the treatment of corticosteroid-responsice dermatoses with secondary infection. Launch Date1957 |
|||
| Curative | NEOSPORIN Approved UseNEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. Launch Date1968 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Bacitracin Inhibits the Migration of U87-MG Glioma Cells via Interferences of the Integrin Outside-in Signaling Pathway. | 2016-03 |
|
| Heparin-binding epidermal growth factor cleavage mediates zinc-induced epidermal growth factor receptor phosphorylation. | 2004-04 |
|
| Thymulin evokes IL-6-C/EBPbeta regenerative repair and TNF-alpha silencing during endotoxin exposure in fetal lung explants. | 2004-03 |
|
| Human peptidoglycan recognition protein-L is an N-acetylmuramoyl-L-alanine amidase. | 2003-12-05 |
|
| Regulated cell surface pro-EGF ectodomain shedding is a zinc metalloprotease-dependent process. | 2003-11-14 |
|
| Zinc modulates mRNA levels of cytokines. | 2003-11 |
|
| Identification of human intestinal alkaline sphingomyelinase as a novel ecto-enzyme related to the nucleotide phosphodiesterase family. | 2003-10-03 |
|
| Prion, amyloid beta-derived Cu(II) ions, or free Zn(II) ions support S-nitroso-dependent autocleavage of glypican-1 heparan sulfate. | 2003-10-03 |
|
| Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters. | 2003-10-01 |
|
| Zinc modulates PPARgamma signaling and activation of porcine endothelial cells. | 2003-10 |
|
| O6-alkylguanine-DNA alkyltransferase: low pKa and high reactivity of cysteine 145. | 2003-09-23 |
|
| Purification of recombinant human apometallothionein-3 and reconstitution with zinc. | 2003-09 |
|
| The acrodermatitis enteropathica gene ZIP4 encodes a tissue-specific, zinc-regulated zinc transporter in mice. | 2003-08-29 |
|
| Redox labile site in a Zn4 cluster of Cu4,Zn4-metallothionein-3. | 2003-08-19 |
|
| Mechanisms of Zn(2+)-induced signal initiation through the epidermal growth factor receptor. | 2003-08-15 |
|
| Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. | 2003-08-01 |
|
| Zinc deficiency induces oxidative DNA damage and increases p53 expression in human lung fibroblasts. | 2003-08 |
|
| Chromium(VI) down-regulates heavy metal-induced metallothionein gene transcription by modifying transactivation potential of the key transcription factor, metal-responsive transcription factor 1. | 2003-07-11 |
|
| Differential effects of zinc on functionally distinct human growth hormone mutations. | 2003-07 |
|
| In vitro effect of metal ions on the activity of two amphibian glyceraldehyde-3-phosphate dehydrogenases: potential metal binding sites. | 2003-06 |
|
| Zinc accumulation in N-methyl-N-nitrosourea-induced rat mammary tumors is accompanied by an altered expression of ZnT-1 and metallothionein. | 2003-06 |
|
| Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase. | 2003-05-02 |
|
| Interrelationships among brain, endocrine and immune response in ageing and successful ageing: role of metallothionein III isoform. | 2003-04 |
|
| Effect of chromium on apolipoprotein A-I expression in HepG2 cells. | 2003-04 |
|
| Changes in rat hepatic gene expression in response to zinc deficiency as assessed by DNA arrays. | 2003-04 |
|
| Copper reduction by copper binding proteins and its relation to neurodegenerative diseases. | 2003-03 |
|
| Indomethacin-induced free radical-mediated changes in the intestinal brush border membranes. | 2003-02-15 |
|
| Effects of zinc occupancy on human O6-alkylguanine-DNA alkyltransferase. | 2003-02-04 |
|
| A novel class of ligand-gated ion channel is activated by Zn2+. | 2003-01-10 |
|
| p53 deficiency accelerates induction and progression of esophageal and forestomach tumors in zinc-deficient mice. | 2003-01-01 |
|
| Activation of the rainbow trout metallothionein-A promoter by silver and zinc. | 2003-01 |
|
| The permissive effect of zinc deficiency on uroguanylin and inducible nitric oxide synthase gene upregulation in rat intestine induced by interleukin 1alpha is rapidly reversed by zinc repletion. | 2003-01 |
|
| Pancreatic metallothionein-I may play a role in zinc homeostasis during maternal dietary zinc deficiency in mice. | 2003-01 |
|
| Zinc-dependent interaction between dishevelled and the Drosophila Wnt antagonist naked cuticle. | 2002-12-13 |
|
| Isolation of GIF from porcine brain and studies of its zinc transfer kinetics with apo-carbonic anhydrase. | 2002-12 |
|
| Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. | 2002-11 |
|
| Zinc transporters in the rat mammary gland respond to marginal zinc and vitamin A intakes during lactation. | 2002-11 |
|
| Zinc enhances the expression of interleukin-2 and interleukin-2 receptors in HUT-78 cells by way of NF-kappaB activation. | 2002-10 |
|
| [Effect of zinc deficiency and zinc replenishment on HOX3.5 gene expression in mouse embryos]. | 2001-11 |
|
| Detection by HPLC-ICP of metallothionein in serum of an epileptic child with valproate-associated hepatotoxicity. | 1992-12 |
|
| Differential dephosphorylation of the insulin receptor and its 160-kDa substrate (pp160) in rat adipocytes. | 1992-07-15 |
|
| In vitro sensitivity of Bacillus proteus and Pseudomonas aeruginosa to seven antibiotics; penicillin, streptomycin, bacitracin, polymyxin, aerosporin, aureomycin, and chloromycetin. | 1950-02 |
|
| Systemic bacitracin in the treatment of progressive bacterial synergistic gangrene. | 1950-02 |
|
| The Use of Bacitracin in Experimental Clostridium Welchii Infection in Guinea Pigs. | 1949-10 |
|
| IN VITRO STUDIES ON POSSIBLE SYNERGISTIC ACTION BETWEEN PENICILLIN AND BACITRACIN. | 1949-09 |
|
| The Results of the Systemic Administration of the Antibiotic, Bacitracin, in Surgical Infections: A Preliminary Report. | 1948-10 |
|
| A Note on the Susceptibility of Hemophilus influenzae Type B to Bacitracin. | 1948-10 |
|
| The relative antisyphilitic activity of penicillins F,G,K, and X and of bacitracin, based on the amounts required to abort early syphilic infections in rabbits. | 1948-03 |
|
| The Action of Bacitracin and Subtilin on Treponema pallidum in Vitro and in Vivo. | 1948-03 |
|
| Bacitracin: Methods of Production, Concentration, and Partial Purification, with a Summary of the Chemical Properties of Crude Bacitracin. | 1948-02 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Curator's Comment: Bacitracin can be used as ophtalmic solution (0.025mg/ml) for the treatment of superficial ocular infections.
400 units, topically
Route of Administration:
Topical
| Substance Class |
Mixture
Created
by
admin
on
Edited
Wed Apr 02 09:38:17 GMT 2025
by
admin
on
Wed Apr 02 09:38:17 GMT 2025
|
| Record UNII |
58H6RWO52I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Related Record | Type |
|---|
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
1284
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-VATC |
QR02AB04
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-ATC |
J01XX10
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 333.120
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 524.155
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-ATC |
R02AB04
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 556.70
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
EPA PESTICIDE CODE |
6302
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 333.110
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 524.154
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 520.154
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-ATC |
D06AX05
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-VATC |
QJ01XX10
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-VATC |
QD06AX05
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-VATC |
QA07AA93
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
BACITRACIN
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
100000092135
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
215-786-2
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
755905
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
SUB00652MIG
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
1291
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | RxNorm | ||
|
BACITRACIN
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | Description: A white or pale brownish yellow powder; odourless or with a faint characteristic odour. Solubility: Freely soluble in water, methanol R and ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Antiinfective drug. Storage: Bacitracin should be kept in a tightly closed container, protected from light and stored at a temperature between 2? and8?C. If it is intended for parenteral administration, the container should be sterile and sealed so as to exclude micro-organisms. Labelling: The designation sterile Bacitracin indicates that the substance complies with the additional requirements for sterileBacitracin and may be used for parenteral administration or for other sterile applications. Additional information: Bacitracin is hygroscopic. Its solutions deteriorate rapidly at room temperature. Even in the absence oflight, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. | ||
|
DB00626
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
58H6RWO52I
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
C295
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
1167
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
m2197
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
N0000008479
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | Decreased Cell Wall Synthesis & Repair [PE] | ||
|
Bacitracin
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
58H6RWO52I
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
D001414
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
1405-87-4
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200558
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
281
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
28669
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY |
All of the following components must be present:
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
MIC
|
||
|
TARGET -> INHIBITOR | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SUB_CONCEPT->SUBSTANCE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities L and N: maximum 8.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities L and N: maximum 8.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities F and G: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities O, P and Q: maximum 2.5 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities F and G: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities O, P and Q: maximum 2.5 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities O, P and Q: maximum 2.5 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
http://apps.who.int/phint/pdf/b/Jb.6.1.40.pdf
|